Jubilant Pharmova Q3 FY2026 Results Show 17% Revenue Growth
Jubilant Pharmova reported a 17% increase in revenue, reaching ₹2,123 Cr for Q3 FY2026, driven by CDMO sterile injectables. EBITDA increased…
PB Fintech Q3 FY26 Earnings Call Highlights Strong Growth & Strategic Vision
PB Fintech reported a 45% YoY growth in total premium for Q3 FY26, driven by a 68% YoY increase in new protection premium. PAT surged by 165%…
Jubilant Pharmova Board Approves Unaudited Financial Results for Q3 2026
Jubilant Pharmova’s Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine…
Jubilant Pharmova Board Approves Unaudited Financial Results for Q3 2026
Jubilant Pharmova’s Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025.…
Puravankara Board Meeting Scheduled to Discuss Financial Results
Puravankara has announced a board meeting scheduled for Thursday, February 12, 2026, to consider and approve the unaudited standalone and…
Ashoka Buildcon Earnings Call Highlights Q3 FY26
Ashoka Buildcon’s Q3 FY26 earnings call highlighted a strategic shift towards quality and sustainability. Key updates included the sale of BOT…
Bank of Baroda To Establish Wholly Owned Subsidiary for Primary Dealer Business
Bank of Baroda has received approval from the Reserve Bank of India (RBI) to establish a wholly-owned subsidiary. This new entity will focus…
Zydus USFDA Grants Orphan Drug Designation for Desidustat
Zydus has received Orphan Drug Designation (ODD) from the USFDA for Desidustat, a novel oral HIF-PHI, to treat Sickle Cell Disease (SCD). The…
NBCC Secures Work Orders Worth Approximately ₹39.5 Crore
NBCC (India) Limited has been awarded work orders amounting to approximately ₹39.5 Crore in the ordinary course of business. These orders span…
Minda Corporation Reports Unaudited Financial Results for Q3 2026
Minda Corporation Limited has announced its unaudited consolidated financial results for the quarter ended December 31, 2025. The company…